Targets › HIB
1 program from 1 company in 1 trial: 1 Phase 1; Infectious disease.
Open in Phaseline: the race on HIB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CanSino Biologics | Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine Haemophilus influenzae type b polysaccharide conjugate vaccine | HIB | Phase 1 | Haemophilus Influenzae Type B Infection | – |
Haemophilus Influenzae Type B Infection (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.